Rudolf Widmann, CEO and founder of AOP Orphan, the first rare disease-specific European company, discusses the overriding goal to ensure rare disease patients are matched with the correct treatments and the importance of open dialogue with specialists and patient groups. Furthermore, he highlights the need to differentiate health technology assessments between rare disease drugs and normal originators to ensure rapid market access to patients.
As the CEO and founder, could you introduce to our international readers AOP Orphan?
"In Austria, we are in a privileged position to be able to offer orphan drugs to our patients as there exists an open mindset when discussing the topic with the reimbursement authorities and dialogue is strong with patient groups."
